Orig3n

Orig3n Overview

Founded 2014
Founded
Status Private
Employees 16
Employees
Latest Deal Type Early Stage VC
Investors 12

Orig3n General Information

Description

Provider of DNA test kits intended to treat rare genetically inherited diseases. The company's DNS tests leverage biological science and technology to provide people with access to information about their genes to make proactive and personalized choices that may impact their well-being, enabling users to be well informed about their body and make informed decisions.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Monitoring Equipment
Other Industries
Information Services (B2C)
Biotechnology
Other Healthcare Technology Systems
Primary Office
  • 27 Drydock Avenue
  • 3rd Floor
  • Boston, MA 02210
  • United States
+1 (800) 000-0000

Orig3n Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Orig3n Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Early Stage VC 08-Nov-2019 000.00 Completed Generating Revenue
4. Early Stage VC (Series B) 11-Jul-2018 0000 000.00 00000 Completed Generating Revenue
3. Early Stage VC (Series A2) 27-Jun-2017 0000 000.00 0000 Completed Generating Revenue
2. Early Stage VC (Series A) 16-Dec-2015 $12.5M $15.6M 0000 Completed Startup
1. Early Stage VC (Series 1) 05-Feb-2015 $3.14M $3.14M 00.000 Completed Startup

Orig3n Cap Table

To view Orig3n‘s complete cap table, request access >>
Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A2 00,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 11,372,211 $0.000100 6% $1.1 $1.1 1x $1.1 13.49%
Series 1 7,498,225 $0.000100 6% $0.42 $0.42 1x $0.42 8.89%

Orig3n Competitors (21)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Verge Genomics Venture Capital-Backed San Francisco, CA 00 000.00 00000000000 000.00
00000 Venture Capital-Backed New York, NY 00 000.00 00000000000 000.00
000000 Venture Capital-Backed Cambridge, MA 00.00 00000000000 00.00
000000 Venture Capital-Backed Mountain View, CA 00 000.00 0000000000 000.00
0000000 Venture Capital-Backed Tübingen, Germany 000 00.000 0000000000 00.000

Orig3n Executive Team (7)

Name Title Board Seat Contact Info
Robin Smith Co-Founder & Chief Executive Officer
Kate Blanchard Co-Founder & Chief Operating Officer
Michael Fang MD Chief Medical Officer

4 Former Executives

Orig3n Board Members (3)

Name Representing Role Since
Byron Smith Mountain Group Partners Board Member 000 0000
Elona Baum DEFTA Partners Board Member 000 0000
Justin Xiang Ph.D Syno Capital Board Member 000 0000

Orig3n Investors (12)

To view Orig3n‘s full investor history, request access >>
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Haitong International Securities Group Hedge Fund Minority 000 0000 000000 0
MMIC Investment Venture Capital Minority 000 0000 000000 0
Vectr Ventures Venture Capital Minority 000 0000 000000 0
Spectrum Health Ventures Corporate Venture Capital Minority 000 0000 000000 0

Orig3n Acquisitions (1)

To view Orig3n‘s complete investment and acquisition history, request access >>
Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000000 000000 22-Nov-2017 000000000000000000 Diagnostic Equipment

Ready to get started?

Request a free trial